LEADER 7: cardiovascular risk profiles of US and European participants in the LEADER diabetes trial differ

Creative Commons License

Rutten G. E. H. M., Tack C. J., Pieber T. R., ÇÖMLEKÇİ A., Orsted D. D., Baeres F. M. M., ...More

DIABETOLOGY & METABOLIC SYNDROME, vol.8, 2016 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 8
  • Publication Date: 2016
  • Doi Number: 10.1186/s13098-016-0153-5
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Keywords: Type 2 diabetes, External validity, Generalizability, Cardiovascular outcome trial, Heterogeneity, RANDOMIZED CONTROLLED-TRIALS, INDIVIDUAL PATIENTS, EXTERNAL VALIDITY, VASCULAR-DISEASE, MANAGEMENT, OUTCOMES
  • Dokuz Eylül University Affiliated: Yes


Aims: To determine whether US and European participants in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial differ regarding risk factors for cardiovascular mortality and morbidity.